Friday, March 24, 2023

Quarterly Refunding Statement of Assistant Secretary for Financial Markets Josh Frost

WASHINGTON — The U.S. Department of the Treasury is offering $96 billion of Treasury securities to refund approximately $67.1 billion of privately-held Treasury notes and bonds maturing on February 15, 2023.  This issuance will raise new cash from private investors of approximately $28.9 billion.  The securities are:

  • A 3-year note in the amount of $40 billion, maturing February 15, 2026;
  •  A 10-year note in the amount of $35 billion, maturing February 15, 2033; and
  • A 30-year bond in the amount of $21 billion, maturing February 15, 2053.

The 3-year note will be auctioned at 1:00 p.m. ET on Tuesday, February 7, 2023.  The 10-year note will be auctioned at 1:00 p.m. ET on Wednesday, February 8, 2023.  The 30-year bond will be auctioned at 1:00 p.m. ET on Thursday, February 9, 2023.  All of these auctions will take place on a yield basis and will settle on Wednesday, February 15, 2023.  

The balance of Treasury financing requirements over the quarter will be met with regular weekly bill auctions, cash management bills (CMBs), and monthly note, bond, Treasury Inflation-Protected Securities (TIPS), and 2-year Floating Rate Note (FRN) auctions.

PROJECTED FINANCING NEEDS AND ISSUANCE PLANS

Treasury believes that current issuance sizes leave it well-positioned to address a range of potential borrowing needs, and as such, does not anticipate making any changes to nominal coupon and FRN new issue or reopening auction sizes over the upcoming February 2023 – April 2023 quarter. 

The table below presents the anticipated auction sizes in billions of dollars for the February 2023 – April 2023 quarter:

 

 

2-Year

3-Year

5-Year

7-Year

10-Year

20-Year

30-Year

FRN

Nov-22

42

40

43

35

35

15

21

22

Dec-22

42

40

43

35

32

12

18

22

Jan-23

42

40

43

35

32

12

18

24

Feb-23

42

40

43

35

35

15

21

22

Mar-23

42

40

43

35

32

12

18

22

Apr-23

42

40

43

35

32

12

18

24

 

Treasury plans to address any seasonal or unexpected variations in borrowing needs over the next quarter through changes in regular bill auction sizes and/or CMBs.

TIPS FINANCING 

Over the February 2023 – April 2023 quarter, Treasury intends to maintain the February 30-year TIPS new issue auction size at $9 billion, maintain the March 10-year TIPS reopening auction size at $15 billion, and maintain the April 5-year TIPS new issue auction size at $21 billion.  Treasury will continue monitor TIPS market conditions and consider whether modest changes would be appropriate in future quarters.

DEBT LIMIT

Since January 19, 2023, Treasury has been using extraordinary measures to finance the government on a temporary basis.[1]  As Secretary Yellen outlined in recent letters to Congress, the period of time that extraordinary measures may last is subject to considerable uncertainty due to a variety of factors, including the challenges of forecasting the payments and receipts of the U.S. government months into the future.  While Treasury is not currently able to provide an estimate of how long extraordinary measures will enable us to continue to pay the government’s obligations, it is unlikely that cash and extraordinary measures will be exhausted before early June.

Until the debt limit is suspended or increased, debt limit-related constraints will lead to greater-than-normal variability in benchmark bill issuance and significant usage of CMBs.

BUYBACK OUTREACH

Treasury continues to study a potential buyback program.  Over the last quarter, Treasury has conducted further outreach with a broad variety of market participants in order to assess the costs and benefits associated with several potential uses for buybacks, including liquidity support and cash and maturity management.  In addition, the Treasury Borrowing Advisory Committee provided additional analysis on buybacks at yesterday’s meeting.  Treasury expects to share its findings on buybacks as part of future quarterly refundings.  Treasury has not made any decision on whether or how to implement a buyback program but will provide ample notice to the public on any decisions.

ADDITIONAL PUBLIC TRANSPARENCY

Treasury supports the work of the Financial Industry Regulatory Authority (FINRA) to enhance its aggregated reports and statistics on Treasury security transactions collected through its Trade Reporting and Compliance Engine.[2]  On February 13, 2023, FINRA’s current weekly reports will be replaced with daily and monthly reports.  The current volume data will also be enhanced with trade counts and, for on-the-run nominal coupons, volume-weighted average price information.  These enhancements should provide market participants with further insights into transaction volumes and pricing in the Treasury securities market.

In remarks at the 2022 U.S. Treasury Market Conference, Under Secretary for Domestic Finance Liang proposed a policy of publicly releasing secondary market transaction data for on-the-run nominal coupons, with end-of-day dissemination and with appropriate cap sizes.  This quarter Treasury gathered views from primary dealers on the proposal.  Treasury plans to continue to engage with market participants on the proposal and will provide updates on progress in upcoming quarters when appropriate.

SMALL-VALUE BUYBACK OPERATION

Treasury regularly conducts periodic testing of existing IT infrastructure to ensure that buyback functionality remains operational.  Within the next three months, Treasury intends to conduct another small-value buyback operation to continue testing the buyback infrastructure.  Details of such an operation will be announced at a later date.

These small-scale buyback operations should not be viewed by market participants as a precursor or signal of any pending policy changes regarding Treasury’s use of buybacks.

Please send comments or suggestions on these subjects or other subjects related to debt management to [email protected].

The next quarterly refunding announcement will take place on Wednesday, May 3, 2023.

 

###

Official news published at https://home.treasury.gov/news/press-releases/jy1238

target=”_blank”>PixaBay

- Advertisement -Reality tv gossip
- Advertisement -publish press release online

GB Sciences’ First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson’s Disease Has Been Issued in China

According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences.

Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has recently been issued a patent in China to protect its proprietary cannabinoid-containing formulation for the treatment of Parkinson's disease. China is an increasingly important pharmaceutical market with cultural acceptance of plant-based formulations, which is a good fit for Gb Sciences' drug candidates. Gb Sciences' first international patent also confirms that the Company's intellectual property strategy can work globally and strengthens the Company's patent portfolio. The global market for treatments of Parkinson's disease is projected to grow to $8.8 billion by the year 2026, and new therapies to address Parkinson's disease symptoms are greatly needed.

"The issuance of Gb Sciences' first international patent protecting methods of using our proprietary cannabinoid-containing formulations for treating Parkinson's disease is an important milestone in the development of these vitally important therapies. Gb Sciences' recent patent issued in China validates both our plant-inspired drug discovery process and intellectual property strategy, which involve defining and protecting Minimum Essential Mixtures," explained Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences, Inc. "Gb Sciences starts its drug discovery process with plant-based therapies that are working anecdotally or in traditional medical systems, then we systematically reduce the number of compounds to reveal Minimum Essential Mixtures. Gb Sciences' novel Minimum Essential Mixtures retain the increased efficacy of whole plant medicines, but they are easier to manufacture with precision at scale like single ingredient drugs. These Minimum Essential Mixtures are a viable alternative to standard single ingredient drugs or traditional whole plant medicines."

Gb Sciences' Minimum Essential Mixture-based drug development strategy does not aim to treat complex diseases as if they were caused by a single factor, but instead addresses the combination of factors that lead to a complex human disorder. Minimum Essential Mixtures (MEMs) are potentially more effective than single ingredient drugs because the different active ingredients target the multiple human processes responsible for complex diseases, such as neurodegeneration, heart disease, and cancers. As such, MEMs may offer a more holistic treatment for complex disorders such as Parkinson's disease that cannot be attributed to a single cause, while maintaining the manufacturing and quality control advantages of single ingredient drugs.

Gb Sciences' patent portfolio currently contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications that cover our novel AI-enabled drug discovery platform and proprietary plant-inspired therapies for more than 65 different disorders. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:
Alexis Quintal
[email protected]


Original Source: GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China
Latest News
Must Read